Shares of DexCom slid after the company reported mixed third-quarter results that included disappointing new patient numbers and lower gross margin guidance. The stock fell 15% to $58.10 and is down ...
DexCom stock drops 15% despite strong Q3 and raised 2025 revenue outlook, as margin concerns and D7 product issues spark uncertainty for future growth. Read more here.
Kessler Topaz Meltzer & Check, LLP encourages DexCom investors who have suffered significant losses to contact the firm directly to acquire more information.
After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...
However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback